HomeStocksBuy CytoMed Therapeutics (GDTC)
GDTC icon

Buy
CytoMed Therapeutics
stock

Sign up to buy GDTC. Start with just $10.

GDTC icon

Buy
CytoMed Therapeutics stocks

Sign up to buy GDTC. Start with just $10.

Sign up
Buy GDTC
USD icon
USD
GDTC icon
GDTC

Only available to USA clients through the Kraken app
or Kraken Pro.

App icon

Kraken

App icon

Pro

App icon

USA

Buy
Buy

Get the Kraken Pro app and buy CytoMed Therapeutics in minutes

Kraken App QR Code

How to buy CytoMed Therapeutics stock on Kraken

Follow these three simple steps to buy shares of CytoMed Therapeutics stock on Kraken. Create your Kraken account in moments and connect your preferred funding method to buy stocks including GDTC. Kraken offers an easy, secure and licensed way to get started.

Create an account

Step 1: Sign up

Provide your email address and country of residence* to create an account and get started with our secure verification process.

Deposit funds

Step 2: Choose a payment method

Send a bank wire, make an ACH purchase, use a debit card or choose from several other payment methods.

Buy

Step 3: Buy CytoMed Therapeutics

Select “Buy stocks” on either Kraken’s web or mobile app and search for your desired stock to start your purchase.

Choose from 11,000+ stocks, ETF and commodities

Buy CytoMed Therapeutics and thousands of popular stocks, ETFs or commodities available on Kraken today (geo restrictions apply). Simply enter the amount you want to spend using your local currency before previewing how much GDTC you will receive. Confirm the stock price, the amount you will purchase and Kraken’s competitive fees before you instantly receive CytoMed Therapeutics in your Kraken account.

GDTC icon
Kraken

In the past 24 hours, GDTC's market capitalization stands at $12.67M, with a daily trading volume of 54.08K shares.

Sign up
Sign up

Why buy CytoMed Therapeutics stocks with Kraken?

Kraken offers a secure and intuitive to buy 11,000+ US listed stocks and ETF stocks in the US, as well as tokenized xStocks for certain regions outside of the US. Use Kraken’s flexible payment methods to buy CytoMed Therapeutics stocks with a debit card, bank transfer or other payment option.

Flexible funding options

Enjoy fast and flexible funding options

Transactions are instant

Buy and sell 11,000+ stocks, ETFs and commodities

Kraken level security

Keep your portfolio secure with Passkeys

Sign up

About CytoMed Therapeutics

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

General stock risks

Investing in stocks is risky and each stock can have its own set of risks. Below is a list of risks that generally apply to all stocks:

Volatility: The performance of stocks can be volatile, with their value dropping as quickly as it can rise. You should be prepared to lose all the money you invest in stocks.

Liquidity: Some stocks may suffer from low liquidity which could prevent you buying or selling them at the price you want or expect.

Complexity: Specific stocks and ETFs may carry with them specific complex risks that are hard to understand. Do your own research and if something sounds too good to be true, it probably is.

Don’t put all your eggs in one basket: Putting all your money into a single type of investment is risky. Spreading your money across different investments makes you less dependent on any one to do well.

If you want to learn more about specific risks related to equity securities, please visit our dedicated equities disclosure page.

Learn more about buying CytoMed Therapeutics stock

Yes. Kraken offers a secure, highly liquid and intuitive way to buy 11,000+ stocks, ETFs and commodities. With advanced trading tools built for both indvidual investors and professional institutions, Kraken offers an all-in-one way to invest in cryptocurrencies, stocks, ETFs and the most important assets for your financial future.

The first step for new invstors looking to buy stocks is to a secure, reputable and competitive stock trading platform such as Kraken. After opening and funding your account. From there, it can be helpful to first research CytoMed Therapeutics and its recent market performance, From there, Kraken makes it easy to buy fractional shares of CytoMed Therapeutics so you can start small and build your portfolio over time.

Yes. Kraken’s mobile app allows you to buy, sell, and manage CytoMed Therapeutics trades on the go from your smartphone.

Earnings reports, product launches, economic data, sector performance, and broad market conditions all influence the price movement of CytoMed Therapeutics stock.

No. Kraken makes it easy to buy fractional shares of CytoMed Therapeutics, meaning you do not need to purchase a full share in order to add CytoMed Therapeutics to your portfolio.

Currently available in the U.S. only; may not be available in all states. Brokerage services are provided by Kraken Securities LLC, member FINRA/SIPC. Please view the firm’s profile, registration and background of our registered reps on https://brokercheck.finra.org/. Digital asset services offered by Payward Interactive, not a member of FINRA/ SIPC and not FDIC insured. This is not an offer, solicitation, inducement or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Kraken Securities is not registered. All trading involves risk, including loss of your investments. View full disclosures at: Equities Disclosures and Crypto Risk Disclosures.

*Stocks are currently only available to customers within the US. This article shall not be deemed marketing, advertising or solicitation for equities offered within any location in which Kraken may not be approved.